Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories

Page 2

Lava breaks through to public markets
Lava Therapeutics, which is developing cancer treatments based on research at Amsterdam University Medical Centers, floated in a $101m offering.
Recursion takes steps toward IPO
The University of Utah spinout is looking to float on the Nasdaq Global Select Market and has filed with a $100m placeholder amount.
Renovacor reaches reverse merger deal
The gene therapy developer focused on cardiovascular and central nervous system diseases will merge with Chardan Healthcare Acquisition 2 Corp to list on NYSE.
Visional to visit public markets
Tokyo University of Science is set to exit the recruitment services group in an IPO in Tokyo.
Evolv graduates to $1.25bn reverse merger
Duke University's contactless security system developer agrees to list through a reverse takeover, providing an exit to OUP.
Design Therapeutics drafts IPO filing
UW Madison’s small-molecule therapy spinout has raised $170m in venture funding since emerging from stealth less than a year ago.
IonQ signs up to $2bn reverse merger
Hyundai, Kia and GV are contributing to a $350 PIPE in support of a reverse merger that will value the Maryland and Duke-linked company at $2bn.
Coursera to class as public company
University of Pennyslvania and Caltech are in line for exits when Stanford’s online education spinout lists on the New York Stock Exchange.
Lava Therapeutics flows toward public markets
Immuno-oncology therapy developer Lava Therapeutics has filed for a $100m IPO, having been set up in 2016 to exploit Amsterdam University Medical Centers research.
Talis takes in IPO proceeds
Caltech spinout Talis Biomedical has raised more than $220m in an initial public offering on the Nasdaq Global Market.

test reg